9.61

2.11% -0.22

Amicus Therapeutics Inc (FOLD)

Overview News Price History Option Chain Financials Why FOLD Down? Discussions Forecast

Amicus Therapeutics Inc stock is traded at $9.61, with a volume of 1.13M. It is down -2.11% in the last 24 hours and up +2.81% over the past month. Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Previous Close:

$9.83

Open:

$9.84

24h Volume:

1.13M

Relative Volume:

0.50

Market Cap:

$2.94B

Revenue:

$493.67M

Net Income/Loss:

$-104.69M

P/E Ratio:

-28.26

EPS:

-0.34

Net Cash Flow:

$-31.51M

1W Performance:

+0.45%

1M Performance:

+2.81%

6M Performance:

-3.77%

1Y Performance:

-25.98%

1-Day Range:

$9.50

$9.84

1-Week Range:

$9.39

$9.95

52-Week Range:

$8.785

$14.03

Amicus Therapeutics Inc Stock (FOLD) Company Profile

Name

Amicus Therapeutics Inc

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

(609) 662-2000

Address

47 HULFISH STREET, PRINCETON, NJ

Employee

517

Twitter

@amicusrx1

Next Earnings Date

2024-11-06

Latest SEC Filings

FOLD's Discussions on Twitter

Compare FOLD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FOLD Amicus Therapeutics Inc	9.615	2.94B	493.67M	-104.69M	-31.51M	-0.34
VRTX Vertex Pharmaceuticals Inc	473.55	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	717.55	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	653.40	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	276.24	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.86	28.75B	3.30B	-501.07M	1.03B	-2.1146

Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-06-24	Initiated	Jefferies	Buy
May-30-24	Initiated	Wells Fargo	Overweight
May-14-24	Upgrade	Guggenheim	Neutral → Buy
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight
Apr-13-22	Resumed	Goldman	Neutral
Jan-14-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Nov-15-21	Upgrade	Stifel	Hold → Buy
Sep-30-21	Upgrade	JP Morgan	Neutral → Overweight
Jul-19-21	Resumed	BTIG Research	Buy
May-27-21	Initiated	Needham	Hold
May-21-21	Initiated	UBS	Buy
Apr-14-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Mar-02-21	Initiated	Stifel	Hold
Feb-12-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-12-21	Downgrade	JP Morgan	Overweight → Neutral
Dec-28-20	Resumed	Cantor Fitzgerald	Overweight
Dec-10-20	Downgrade	Citigroup	Buy → Neutral
Nov-11-20	Initiated	Berenberg	Hold
Jun-17-20	Initiated	BTIG Research	Buy
Feb-04-20	Resumed	Cantor Fitzgerald	Overweight
Nov-12-19	Reiterated	H.C. Wainwright	Buy
Jun-17-19	Initiated	H.C. Wainwright	Buy
Jun-05-19	Reiterated	Cantor Fitzgerald	Overweight
Apr-05-19	Initiated	Janney	Buy
Jan-30-19	Initiated	Cantor Fitzgerald	Overweight
Oct-29-18	Initiated	Citigroup	Neutral
Aug-17-18	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-06-17	Resumed	Goldman	Neutral
Sep-13-17	Reiterated	Chardan Capital Markets	Buy
Aug-10-17	Reiterated	Chardan Capital Markets	Buy
Jan-24-17	Upgrade	Robert W. Baird	Neutral → Outperform
May-18-16	Initiated	BofA/Merrill	Buy
Apr-14-16	Initiated	Robert W. Baird	Neutral
Apr-12-16	Reiterated	Chardan Capital Markets	Buy
Sep-16-15	Downgrade	Chardan Capital Markets	Buy → Neutral
Jun-16-15	Reiterated	Chardan Capital Markets	Buy

View All

Amicus Therapeutics Inc Stock (FOLD) Latest News

11:28 AM

A new trading data show Amicus Therapeutics Inc (FOLD) is showing positive returns. - SETE News

11:28 AM

Feb 06, 2025

27,523 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Purchased by Tempus Wealth Planning LLC - MarketBeat

Feb 06, 2025

Feb 05, 2025

BlackRock, Inc. Expands Holdings in Amicus Therapeutics Inc - GuruFocus.com

Feb 05, 2025

Potential Price Increase for Amicus Therapeutics Inc (FOLD) After Recent Insider Activity - Knox Daily

Feb 05, 2025

Feb 03, 2025

Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025 - GlobeNewswire

Feb 03, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by SG Americas Securities LLC - Defense World

Feb 03, 2025

Zacks Research Has Negative Outlook of FOLD FY2025 Earnings - Defense World

Feb 03, 2025

Jan 27, 2025

Amicus Therapeutics (NASDAQ:FOLD) shareholders have endured a 26% loss from investing in the stock a year ago - Simply Wall St

Jan 27, 2025

13,028 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Acquired by Park Avenue Securities LLC - Defense World

Jan 27, 2025

Jan 26, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Inspire Investing LLC - MarketBeat

Jan 26, 2025

Jan 23, 2025

Research Analysts Set Expectations for FOLD Q4 Earnings - Defense World

Jan 23, 2025

Jan 22, 2025

Amicus Therapeutics expects 2024 revenue slightly above consensus, guides 2025 - MSN

Jan 22, 2025

Leerink Partnrs Issues Optimistic Estimate for FOLD Earnings - MarketBeat

Jan 22, 2025

Jan 21, 2025

Research Analysts Set Expectations for FOLD Q2 Earnings - MarketBeat

Jan 21, 2025

Assenagon Asset Management S.A. Has $4.49 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Jan 21, 2025

Assenagon Asset Management S.A. Reduces Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World

Jan 21, 2025

Jan 20, 2025

Is Amicus Therapeutics (FOLD) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey

Jan 20, 2025

Jan 17, 2025